ACSS2

Across TCGA pan-cancer cohorts, ACSS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACSS2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACSS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACSS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where ACSS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.502	0.271	.001	38	view →
CCRCC	DFS	Tertile	All	1.000	0.483	.010	20	view →
LUAD	DFS	Quartile	II,III,IV	1.000	0.839	.005	7	view →
GBM	DFS	Tertile	All	0.488	0.270	.012	3	view →
HNSC	DFS	Quartile	III,IV	0.949	0.324	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACSS2–PDAC (OS)

Open the PDAC breakdown →